Several important developments in the pharmacotherapy of treatment-resistant schizophrenia have occurred over the past year. These developments include the resolution of questions related to the clinical application and safety of clozapine, the widespread introduction of risperidone, and new approaches to the treatment of negative symptoms and cognitive impairment. These developments will be critically examined and future challenges for the management of treatment-resistant schizophrenia will be discussed.